Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aggravated airway inflammation: biological treatment with Mepolizumab
2020-000421-76Phase 4Completed
- Sponsor
- Helsinki University Hospital
- Start
- Mar 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, single-arm trial of mepolizumab in chronic rhinosinusitis with nasal polyps (CRSwNP), asthma and nonsteroidal anti-inflammatory drug-exacerbated respiratory disease (AERD), sponsored by Helsinki University Hospital. Primary endpoints: nasal polyp score, SNOT-22 symptom score and 2 more. Started Mar 2020; status: completed.
02
Drugs
mepolizumab
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)asthmanonsteroidal anti-inflammatory drug-exacerbated respiratory disease (AERD)
Beyond the preview
Go deeper on 2020-000421-76.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000421-76.